Viking Therapeutics, Inc. (0VQA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Viking Therapeutics fourth quarter and full year 2025 financial results conference call. At this time, all participants will be in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star key, followed by the one on your telephone keypad. If anyone has difficulty hearing the conference, please press star, then zero for operator assistance. As a reminder, this conference call is being recorded today, February 11th, 2026. I would now like to turn the call over to Vikings Manager of Investor Relations, Ms. Stephanie Diaz. Please go ahead, Stephanie. Hello, and thank you all for participating in today's call. Joining me today is Brian Land, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 11, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments. Thanks, Stephanie, and good afternoon to everyone listening in by ...